ELIAS Animal Health develops ELIAS Cancer Immunotherapy (ECI®), a first-in-class adoptive cell therapy that utilizes a dog's own activated T cells to target and eliminate cancer cells, particularly in cases of bone cancer. This personalized treatment addresses the high incidence of cancer in dogs, providing a viable alternative to traditional chemotherapy and radiation therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer is a leading cause of death in dogs, often diagnosed in late stages when treatment options are limited. Traditional cancer treatments like chemotherapy and radiation can have significant side effects, impacting the pet's quality of life. There is a need for more effective and less invasive cancer therapies for canines.
Solution
ELIAS Animal Health offers ELIAS Cancer Immunotherapy (ECI®), an autologous adoptive cell therapy that utilizes a dog's own immune system to target and eliminate cancer cells. The treatment involves vaccinating the dog with its own cancer cells to stimulate an immune response. T cells are then collected via apheresis, activated ex vivo to create a large population of killer T cells, and reinfused into the patient. This personalized approach aims to prolong the dog's life and improve its quality of life by leveraging the power of its own immune system.
Target Audience
The primary target audience includes veterinarians and pet owners seeking alternative cancer treatment options for dogs, particularly those looking for therapies that improve quality of life and prolong survival.
Features
- Autologous adoptive cell therapy using the patient's own T cells
- Ex vivo T cell activation to enhance cancer-killing capabilities
- Personalized vaccine derived from the patient's own cancer cells
- Treatment protocol designed to minimize the need for chemotherapy or radiation
- Demonstrated effectiveness in multiple rodent and human cancers